The overestimation of concentric hypertrophy in patients with HFpEF as determined by 2D-echocardiography

Mohammad F. Mathbout¹, Hussam Al Hennawi²*, Anwar Khedr³, Gaurang N. Vaidya⁴, Marcus Stoddard⁵

ABSTRACT

Background: Heart failure with preserved ejection fraction continues to pose multiple challenges in terms of accurate diagnosis, treatment, and associated morbidity. Accurate left ventricular (LV) mass calculation yields essential prognostic information relating to structural heart disease. Two-dimensional (2D) echocardiography-based calculations are solely limited to LV geometric assumptions of symmetry, whereas three-dimensional (3D) echocardiography could overcome these limitations. This study aims to compare the performance of 2D and 3D LV mass calculations.

Methods: A prospective review of echocardiography findings at the University of Louisville, Kentucky, was conducted and assessed. Normal ejection fraction (EF) was defined as >=52% in males and >=54% in females. The following calculations were performed: relative wall thickness (RWT) = 2x posterior wall thickness/LV internal diastolic dimension (LVIDd) and 2D LV mass = 0.8[1.04(LVIDd + IVSd +PWd³ − LVIDd³)] + 0.6. Concentric hypertrophy was RWT >0.42 and LV mass >95 kg/m² in females or >115 kg/m² in males. The same cut-offs were used for 2D and 3D echocardiography.

Results: Echocardiographic findings for a total number of 154 patients in the study were investigated. There was a weak positive correlation between 2D and 3D LV mass indices (R = 0.534, r² = 0.286, p = 0.001). Seventy patients had 3D EF >=45% with clinical heart failure (HFpEF). Among HFpEF patients, LV hypertrophy (LVH) was present in 74% of patients by 2D echocardiography and 30% by 3D echocardiography (McNemar test p = 0.001). Using 3D echocardiography as the reference, 68% of normal patients were misdiagnosed with LV hypertrophy by 2D echocardiography. Two-thirds of the patients with concentric remodeling by 3D echocardiography were misclassified as having concentric hypertrophy by 2D echocardiography (p = 0.001).

Conclusion: Adapting necropsy-proven LV mass index cutoffs, 2D over-diagnosed LV hypertrophy through overestimation of the mass, compared to 3D echocardiography. In turn, the majority of HFpEF patients showed no structural hypertrophy of the LV on 3D imaging. This suggests that the majority of patients with HFpEF may qualify for pharmacological prevention to prevent further progression to LV remodeling or LVH.
BACKGROUND

Among different parameters used to assess left ventricular (LV) function, left ventricular ejection fraction (LVEF) remains the most widely used echocardiographic parameter which provides an independent predictor of mortality and further direct patient management. Operator-dependent 2-dimensional (2D) and 3-dimensional (3D) echocardiographic imaging provides both quantitative and qualitative assessments of the LV hemodynamic functions necessary for optimal cardiac evaluation. While both can assess LVEF, 2D echocardiography LVEF assessment is largely dependent on the reader’s experience and imaging plane with varying accuracy according to imaging quality. Newly emerged techniques used for LV functional evaluation include temporal speckle-tracking echocardiography (STE), which depicts LV myocardial deformation parameters, including global longitudinal strain (GLS). Unlike EF evaluation, GLS provides reproducible readings subject to subtle changes in LV function prior to imminent changes in EF in different disease states amenable to medical treatment. Moreover, different studies have reported more accurate mortality predictions associated with GLS than with EF.

Although most outcome predicting studies have utilized 2D echocardiography (2DE) to evaluate LV function, 3D echocardiography (3DE) has been shown to provide superior LV size and function evaluations in terms of reproducibility and function. This is largely due to overcoming apical foreshortening and the acquisition of measurements that are mainly based on direct volumetric measurements in the absence of geometrical presumptions. Of note, in the era of imaging advances, growing evidence has shown that 3DE has provides better visualization of LV morphology analysing different parameters including relative wall thickness (RWT) outlining early stages of myocardial hypertrophy confidently tied with further diagnostic and prognostic outcomes. Therefore, we hypothesized that 3DE analytical tools can better predict ensuing myocardial changes in patients with HFpEF, making them candidates for an early course of pharmacological treatment.

Methods

A prospective review of echocardiography findings at the University of Louisville, Kentucky, was conducted and assessed. Normal ejection fraction (EF) was defined as \( \geq 52\% \) in males and \( \geq 54\% \) in females. The following calculations were performed:

Relative wall thickness (RWT) = \( 2 \times \frac{\text{posterior wall thickness}}{\text{LV internal diastolic dimension (LVIDd)}} \)

2D LV mass = \( 0.8 \times 1.04 \times (\text{LVIDd} + \text{IVSd} + \text{PWd})^3 - \text{LVIDd}^3) + 0.6 \)

Concentric hypertrophy was RWT >0.42 and LV mass >95 kg/m\(^2\) in females or >115 kg/m\(^2\) in males. Same cutoffs were used for 2D and 3D echocardiography.

RESULTS

Echocardiographic findings for a total number of 154 patients in the study were investigated. There was a weak positive correlation between the 2D and 3D LV mass indices \( (R = 0.534, r^2 = 0.286, P = 0.001) \) (Figure 1). Seventy patients had 3D EF \( \geq 45\% \) with clinical heart failure (HFpEF). Among HFpEF patients, LV hypertrophy (LVH) was present in 74% of patients by 2D and 30% by 3D echocardiography (McNemar test \( P = 0.001 \)). Using 3D echocardiography as the reference, 68% of the normal patients were misdiagnosed as LV hypertrophy by 2D (Table 1). Two-thirds of the patients with...
Table 1  Comparison of 2D and 3D interpretation of LV mass index.

| 2D interpretation | P-value |
|-------------------|---------|
|                   |         |
| Normal            | LV Hypertrophy |
| 3D interpretation | Normal   | 16 (32%) | 33 (68%) | 0.04 |
|                   | LV Hypertrophy | 2 (10%) | 19 (90%) |

concentric remodeling by 3D echocardiography were misclassified as having concentric hypertrophy by 2D echocardiography ($p = 0.001$).

**DISCUSSION**

The pathogenesis of HFrEF is still not completely understood. The pathophysiology of HFrEF can be explained by two theories. The old conventional theory holds that systemic hypertension is the primary cause of left ventricular remodeling. Concentric left ventricular hypertrophy, fibrosis, and diastolic dysfunction result from pressure overload, leading to left atrial hypertension and remodeling. These processes can lead to pulmonary hypertension and atrial fibrillation. Finally, diastolic dysfunction in the left ventricle causes right ventricular and atrial remodeling, as well as concomitant right ventricular diastolic and systolic dysfunction. In addition to systemic hypertension, a novel emerging theory considers metabolic disorders such as obesity, metabolic syndrome, and type 2 diabetes mellitus. These pro-inflammatory comorbidities produce microvascular endothelial inflammation. This results in coronary microvascular inflammation, decreased density, cardiac interstitial fibrosis, and increased oxidative stress, leading to cardiomyocyte hypertrophy and stiffness. The previous factors result in myocardial hypertrophy, remodeling, and dysfunction.

Left ventricular wall remodeling is considered one of the most important pathophysiological factors predisposing to overt heart failure. Different patterns of left ventricular (LV) remodeling have been described, including normal geometry, concentric remodeling, concentric hypertrophy, and eccentric hypertrophy. Stemming from geometrical changes that can be detected at earlier stages, the current consensus
on LV chamber measurements advises the characterization of LV geometry based on echocardiographically determined LV mass index (LVMI) and relative wall thickness (RWT)\(^8\). Healthy geometry is identified by normal LVMI and RWT. Compared to other disorders, concentric remodeling is characterized by increased RWT, whereas both eccentric and concentric hypertrophy are marked by increased LVMI with normal RWT in the former and increased RWT in the latter. Moreover, concentric hypertrophy can be differentiated by an increase in short-axis diameter compared to an increase in myocyte length in eccentric hypertrophy, which is evident microscopically\(^9\). Although LV geometric abnormalities can be detected at early stages of LV remodeling, heart failure has over the years been staged by LV ejection fraction (LVEF) instead of LV geometry. This has recently conflicted with experts’ opinions recommending that early recognition of geometric abnormalities can preserve normal heart function and provide accurate estimation beyond what is expected from ejection fraction alone\(^10\).

Left ventricular remodeling and hypertrophy were found to be the most common abnormal geometric abnormalities in patients with HfP EF in most epidemiological studies, registries, and clinical trials (Tables 2, 3)\(^11\). In addition, patients with HfP EF are reported to have more prominent concentric hypertrophy than those with hypertensive heart disease who do not have HfP EF\(^12\).\(^18\). It was also found that LVH had a reverse correlation with exercise capacity. Among all geometric types, patients with LV concentric hypertrophy showed the greatest exercise limitation due to reduced contractility and chronotropic incompetence\(^19\). Moreover, LVH was found to be a strong predictor of heart failure hospitalization, cardiovascular death, or aborted cardiac arrest. In this study, LV concentric remodeling and hypertrophy were the most common abnormal geometric findings associated with an increased risk of hospitalizations inferred from the TOPCAT trial\(^16\).

Heart failure with preserved ejection fraction (HfP EF) is a clinical syndrome that accounts for half of all heart failure (HF) patients and has been increasing in prevalence.

### Table 2 Prevalence of LV concentric remodeling and hypertrophy in patients with HfP EF in selected epidemiological studies and registries.

|                      | Normal geometry | Left ventricular remodeling | Left ventricular concentric hypertrophy | Left ventricular eccentric hypertrophy |
|----------------------|-----------------|-----------------------------|----------------------------------------|---------------------------------------|
| Olmsted County\(^4\) | 31%             | 27%                         | 26%                                    | 16%                                   |
| ARIC study\(^6\)     | 5%              | 20%                         | 73%                                    | 2%                                    |
| Northwestern registry\(^7\) | 12%          | 28%                         | 48%                                    | 12%                                   |

### Table 3 Prevalence of LV concentric remodeling and hypertrophy in patients with HfP EF in selected epidemiological studies and registries.

|                | Normal geometry | Left ventricular remodeling | Left ventricular concentric hypertrophy | Left ventricular eccentric hypertrophy |
|----------------|-----------------|-----------------------------|----------------------------------------|---------------------------------------|
| PARAMOUNT\(^8\) | 72%             | 14%                         | 7%                                     | 7%                                    |
| I-PRESERVE\(^9\) | 46%             | 25%                         | 29%                                    | 0%                                    |
| PARAGON-HF\(^10\) | 46%             | 33%                         | 12%                                    | 9%                                    |
| TOPCAT\(^11\)   | 14%             | 34%                         | 43%                                    | 9%                                    |
attributing to major cardiovascular mortality. HFpEF expands beyond abnormalities strictly to LV diastolic function and is considered a spectrum of diseases that encompasses limitations in cardiac, vascular, and peripheral functions. On the other hand, LV diastolic dysfunction plays a cardinal role in the pathophysiology of HFpEF. LV diastolic dysfunction is characterized by an impairment of heart muscle relaxation, an increase in viscoelastic chamber stiffness (decreased compliance), or a combination of the two. This results in symptomatic HF stemming from the congestion of the vascular system and other vital organs, giving rise to a range of symptoms, including dyspnea, impairment of daily activities at rest, and exertion.

Hemodynamic impairments associated with circulatory pump failure predispose patients to recurrent hospitalization, diminished quality of life (QoL), and decreased survival. Early HFpEF phenotyping is crucial to halt further progression and may impart necessary measures for targeted therapies to this specific subpopulation of patients positioned to attain the greatest benefit. Cardiovascular imaging, and echocardiography in particular, plays a vital role in the diagnosis and assessment of HFpEF, which evaluates cardiac structure, hemodynamics, and function. While the diagnosis of HFpEF is clear in symptomatic patients with signs of overt congestion, diagnosing euvolemic patients with marked exertional dyspnea poses a considerable challenge.

CONCLUSION

HFpEF continues to pose multiple challenges concerning accurate diagnosis, treatment, and associated morbidity. Cardiovascular imaging provides important information necessary for accurate diagnosis at early stages in patients who may require treatment to halt further progression. In particular, echocardiography assesses cardiac function and accurately identifies abnormal geometric changes; therefore, clinical suspicion warrants evaluation.

Since LV remodeling and concentric hypertrophy are the most common geometric changes in HFpEF and constitute the cornerstone of HFpEF pathogenesis, it is essential to identify these changes before progression to more advanced stages. This study adds value to the diagnostic and prognostic utility of 3D echocardiographic functional indices to identify LV remodeling and concentric hypertrophy early in order to risk-stratify patients and drive their management accordingly.

REFERENCES

[1] Nelson GR, Cohn PF, Gorlin R. Prognosis in medically-treated coronary artery disease: influence of ejection fraction compared to other parameters. Circulation. 1975;52(3):408–412. doi: 10.1161/01.cir.52.3.408.
[2] Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–883. doi: 10.1056/NEJMoa013474.
[3] Solomon SD, Anavekar N, Skali H, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Wang D, Pocock S, Pfeffer MA. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112(24):3738–3744. doi: 10.1161/CIRCULATIONAHA.105.561423.
[4] Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, Josephson ME, Lehmann MH, Prystowsky EN. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007;50(12):1150–1157. doi: 10.1016/j.jacc.2007.04.095.
[5] Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014;100(21):1673–1680. doi: 10.1136/heartjnl-2014-305538.
[6] Morris DA, Otani K, Bektani T, Takigiku K, Izumi C, Yuda S, Sakata K, Ohte N, Tanabe K, Friedrich K, Kühnle Y, Nakatani S, Otsuji Y, Havercamp W, Boldt LH, Takeuchi M. Multidirectional global left ventricular systolic function in normal subjects and patients with hypertension: multcenter evaluation. *J Am Soc Echocardiogr*. 2014;27(5):493–500 doi: 10.1016/j.echo.2014.01.017.

[7] Nahum J, Bensadú A, Dussault C, Mcaron L, Clémence D, Bouhemad B, Monin JL, Rande JL, Gueret P, Lim P. Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patients. *Circ Cardiovasc Imaging*. 2010;3(3):249–256 doi: 10.1161/CIRCIMAGING.109.910893.

[8] Motoki H, Borowski AG, Shrestha K, Troughton RW, Tang WH, Thomas JD, Klein AL. Incremental prognostic value of assessing left ventricular myocardiak mechanics in patients with chronic systolic heart failure. *J Am Coll Cardiol*. 2012;60(20):2074–2081 doi: 10.1016/j.jacc.2012.07.047.

[9] Ersbell M, Valeur N, Møgensen UM, Andersen MJ, Møller JE, Hassager C, Søgaard P, Køber L. Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. *J Am Coll Cardiol*. 2013;62(33):2365–2373.

[10] Krishnasamy R, Isbel NM, Hawley CM, Pascoe EM, Burrage M, Leano R, Haluska BA, Marwick TH, Stanton T. Left ventricular global longitudinal strain (GLS) is a superior predictor of all-cause and cardiovascular mortality when compared to ejection fraction in advanced chronic kidney disease. *PLOS ONE*. 2015;10(6):e0127044 Published 2015 May 15. doi: 10.1371/journal.pone.0127044.

[11] Doros JL, Lezotte DC, Weitzenkamp DA, Allen LA, Salcedo EE. Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis. *J Am Coll Cardiol*. 2012;59(20):1799–1808 doi: 10.1016/j.jacc.2012.01.037.

[12] Maffessanti F, Caiani EG, Tamborini G, Muratori M, Sugeng L, Weinert L, Alamanni F, Zanobini M, Morev V, Lang RM, Pepi M. Serial changes in left ventricular shape following early mitral valve repair. *Am J Cardiol*. 2010;106(6):836–842 doi: 10.1016/j.amjcard.2010.04.044.

[13] Vadakkumpadan F, Trayanova N, Wu KC. Image-based left ventricular shape analysis for sudden cardiac death risk stratification. *Heart Rhythm*. 2014;11(10):1693–1700 doi: 10.1016/j.hrthm.2014.05.018.

[14] Gladden JD, Linke WA, Redfield MM. Heart failure with preserved ejection fraction. *Pflogers Archiv*. 2014;466(6):1037–1053 doi: 10.1007/s00424-014-1480-8.

[15] Redfield MM. Heart failure with preserved ejection fraction. *N Engl J Med*. 2016;375(19):1868–1877 doi: 10.1056/NEJMc1511175.

[16] Zakeri R, Cowie MR. Heart failure with preserved ejection fraction: controversies, challenges and future directions. *Heart*. 2018;104(5):377–384 doi: 10.1136/heartjnl-2016-310790.

[17] Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. *J Am Coll Cardiol*. 2013;62(4):263–271 doi: 10.1016/j.jacc.2013.02.092.

[18] Lang RM, Badano LP, Mor-Avi V, Milialo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JJ. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the european association of cardiovascular imaging. *J Am Soc Echocardiogr*. 2015;28(1):1–39 e1401. doi: 10.1016/j.echo.2014.10.003.

[19] Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. *Nat Rev Cardiol*. 2018;15(7):387–407 doi: 10.1038/s41569-018-0007-y.

[20] Tripodiadis F, Butler J, Abboud FM, Armstrong PW, Adamopoulos S, Atherton JJ, Backs J, Bauersachs J, Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong Gupta DK, Shah AM, Castagno D, Takeuchi M, Loehr LR, Fox ER, Butler KR, Mosley TH, Kitzman JD, Beussink L, Sauer AJ, Freed BH, Burke MA, Shah SJ. Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction from Olmsted County, Minnesota [published correction appears in Circulation. 2007 May 22;115(20):e535]. *Circulation*. 2007;115(5):1982–1990 doi: 10.1161/CIRCULATIONAHA.106.659763.

[21] Gupta DK, Shah AM, Castagno D, Takeuchi M, Loehr LR, Fox ER, Butler KR, Mosley TH, Kitzman DW, Solomon SD. Heart failure with preserved ejection fraction in African Americans: the ARIC (Atherosclerosis Risk In Communities) study. *JACC Heart Fail*. 2013;1(2):156–163 doi: 10.1016/j.jchf.2013.01.003.

[22] Katz DH, Beussink L, Sauer AJ, Freed BH, Burke MA, Shah SJ. Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. *Am J Cardiol*. 2013;112(8):1158–1164 doi: 10.1016/j.amjcard.2013.05.061.

[23] Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. *Lancet*. 2012;380(9851):1387–1395 doi: 10.1016/S0140-6736(12)62276-6.

[24] Zile MR, Gottlieb JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. *Circulation*. 2011;124(23):2491–2501 doi: 10.1161/CIRCULATIONAHA.110.011031.
[26] Shah AM, Cikes M, Prasad N, Li G, Getchevski S, Claggett B, Rizkala A, Lukashevich I, O'Meara E, Ryan J, Shah SJ, Mullens W, Zile MR, Lam CSP, McMurray J, Solomon SD. Echocardiographic features of patients with heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2019;74(23):2858–2873 doi: 10.1016/j.jacc.2019.09.063.

[27] Shah AM, Claggett B, Swetz FK, Shah SJ, An IS, O'Meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) Trial. Circ Heart Fail. 2014;7(5):740–751 doi: 10.1161/CIRCHEARTFAILURE.114.001583.

[28] Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49(2):198–207 doi: 10.1016/j.jacc.2006.08.050.

[29] Lam CS, Grewal J, Borlaug BA, Ommen SR, Kane GC, McCully RB, Pellikka PA. Size, shape, and stamina: the impact of left ventricular geometry on exercise capacity. Hypertension. 2010;55(5):1143–1149 doi: 10.1161/HYPERTENSIONAHA.109.146845.

[30] Owan TE, Hodge DO, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–259 doi: 10.1056/NEJMoa052256.

[31] Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507–515 doi: 10.1038/nrcardio.2014.83.

[32] Brutsaert DL, Sys SU, Gillebert TC. Diastolic failure: pathophysiology and therapeutic implications [published correction appears in J Am Coll Cardiol 1993 Oct;22(4):1272]. J Am Coll Cardiol. 1993;22(1):318–325 doi: 10.1016/0735-1097(93)90850-z.

[33] Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004;55:373–394 doi: 10.1146/annurev.med.55.091902.104417.

[34] Nagueh SF, Smiseth OA, Appleton CP, Byrd 3rd BF, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the american society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29(4):277–314 doi: 10.1016/j.echo.2016.01.011.

[35] Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. Evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138(9):861–870 doi: 10.1161/CIRCULATIONAHA.118.034646.

[36] Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation. 2017;135(9):825–838 doi: 10.1161/CIRCULATIONAHA.116.024822.

[37] Borlaug BA, Nishimura RA, Soriaja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3(5):588–595 doi: 10.1161/CIRCHEARTFAILURE.109.930701.